CHARLOTTESVILLE, Va., Nov. 2, 2023 /PRNewswire/ — RIVANNA┬«, a leading developer of imaging-based medical solutions, is pleased to announce that they have received a substantial grant of $2.9 million from the National Institutes of Health (NIH). This grant will be instrumental in further advancing the development of their cutting-edge technology, Accuro┬« 3S, designed specifically for image-guided regional anesthesia. The primary goal is to broaden access to opioid-sparing analgesia and provide effective pain management for individuals suffering from hip fractures.

Every year, over 330,000 Americans are hospitalized due to hip fractures, necessitating immediate pain relief and surgical intervention for mobility restoration and to reduce mortality risks. Traditional treatment methods involve the use of parenteral opioids, which unfortunately can lead to various adverse effects, including recurrent opioid use. To counteract these complications, ultrasound-guided regional anesthesia (UGRA), such as the pericapsular nerve group (PENG) block, offers a viable opioid-free alternative for approximately 300,000 patients annually. However, the adoption of UGRA is hampered by several barriers, such as limited provider experience and specialized training requirements.

This is where Accuro 3S comes into play as it represents a significant technological advancement aimed at overcoming UGRA barriers. By equipping healthcare providers with workflow intelligence for hip regional anesthesia, this groundbreaking technology reduces training requirements, streamlines workflow processes, and ultimately enhances the utilization of hip regional anesthesia for pain management in hip fracture cases. The Accuro 3S system boasts several notable innovations, including AI-based reconstructions of hip anatomy, real-time needle guidance with automated identification of crucial anatomical landmarks, and the integration of a novel ultrasound probe.

The CEO and co-founder of RIVANNA, Will Mauldin, PhD, commented on the importance of expanding opioid-sparing UGRA techniques for hip fracture pain, stating, “Considering that more than one million PENG blocks are performed annually across 5,000 U.S. emergency departments, there is a pressing need to expand opioid-sparing UGRA for hip fracture pain, enhancing accessibility to safer medical procedures and improving patient outcomes.” Dr. Mauldin also highlighted the immense market opportunity this technology presents, estimated at a significant $295 million annually in the United States alone.

The grant received by RIVANNA is part of the NIH HEAL (Helping to End Addiction Long-term) Initiative and is being supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award Number R44AR083337. This backing is a testament to the potential of Accuro 3S and its ability to positively impact patient care and public health.

How AI legalese decoder Can Help with the Situation?

One of the key challenges in the medical field is jargon-filled legal language. The use of AI legalese decoder can greatly assist healthcare providers, researchers, and legal professionals in understanding and translating complex legal terms and regulatory language. This decoder will enable clear and concise communication between stakeholders, allowing for smoother collaboration and increased efficiency in navigating grant applications, regulatory compliance, and intellectual property matters.

About RIVANNA

RIVANNA┬« is a remarkable medical device innovator and manufacturer based in Charlottesville, VA. The company’s mission is to develop and commercialize world-first imaging-based medical technologies that elevate global standards of care. Their unique value proposition lies in a patented ultrasound-based bone imaging technology, which enables radiation-free alternatives to X-ray-based imaging, enhancing patient safety. Furthermore, RIVANNA leverages AI-enabled software to increase provider precision and efficiency. Operating from an FDA-registered and ISO 13485:2016 certified manufacturing facility, RIVANNA is committed to producing the Accuro┬« product line and other related medical equipment and components. For more information, please visit┬áRIVANNA.

SOURCE Rivanna Medical